<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/17BF6965-68C3-4560-8BC2-28AC2D489890"><gtr:id>17BF6965-68C3-4560-8BC2-28AC2D489890</gtr:id><gtr:name>University of Virginia</gtr:name><gtr:address><gtr:line1>P.O. Box 3818</gtr:line1><gtr:postCode>22903</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/17BF6965-68C3-4560-8BC2-28AC2D489890"><gtr:id>17BF6965-68C3-4560-8BC2-28AC2D489890</gtr:id><gtr:name>University of Virginia</gtr:name><gtr:address><gtr:line1>P.O. Box 3818</gtr:line1><gtr:postCode>22903</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F10180EA-AAA4-4F86-A57D-9D75AC847337"><gtr:id>F10180EA-AAA4-4F86-A57D-9D75AC847337</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Cobbold</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G108%2F574"><gtr:id>8FF78630-352E-4325-9600-600FA9AB66A4</gtr:id><gtr:title>The development of cellular therapy for the correction of CMV-specific immunodeficiency after stem cell transplantation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G108/574</gtr:grantReference><gtr:abstractText>Bone marrow transplants (BMT) are commonly used to treat patients with leukaemia or inherited diseases of the bone marrow. Unfortunately, the procedure leaves patients with a very weakened immune system for a few months after transplant and they often suffer from severe infections. One of these is a virus called cytomegalovirus (CMV) which many of us carry but which rarely causes disease in healthy people.
We propose to study the details of how patients mount an immune response to CMV after BMT and to understand why some patients clear the infection whereas others get severe infection. 
In addition we can now identify which patients are going to get severe disease and we are able to transfer immune cells from their transplant donor as a treatment. We now plan to optimise this treatment so that we deliver these cells at the most appropriate time and to the patients at greatest risk.
The work should lead to better control of CMV in our patients and will act as a model for the treatment of a wide range of serious infections in transplant patients.</gtr:abstractText><gtr:technicalSummary>Allogeneic stem cell transplantation (SCT) is commonly used to treat malignant and inherited diseases of the bone marrow and involves replacing the bone marrow and haemopoietic system of a transplant patient with those of a donor. Unfortunately, the procedure continues to be complicated by an intense period of immunosuppression following transplantation which can lead to severe infectious complications. Cytomegalovirus (CMV) is a common pathogen in this setting and commonly leads to morbidity and mortality in SCT patients. Impaired cellular immunity to CMV leads directly to viral reactivation and approaches to correct this deficiency by directly infusing donor-derived CD8+ CMV-specific T cell clones which have been expanded in vitro have been reported.
My MRC Clinical Training Fellowship involved study of CMV-specific CD8+ T cell immune reconstitution in patients following SCT. I also initiated a phase I clinical trial in which CMV-specific CD8+ T cells are magnetically selected from the transplant donor and infused into the patient directly without ex vivo manipulation. Seven patients have currently been treated in what is the first clinical trial of this kind in the world.
In this application I wish to extend both of these studies in order to learn more about the determinants of the immune response to CMV and to optimise the cellular correction of CMV-specific immunotherapy. I propose to study the mechanisms that govern the functional activity of CMV-specific CTL post-SCT and to identify new CMV epitopes that may act as targets for immunotherapy. I plan to spend a year with Professor Victor Engelhard in North Carolina whose research group is the world leader in proteomic analysis of peptide epitopes. The second phase of the Fellowship application is concerned with the further development of clinical trials on the cellular correction of CMV-immunodeficiency. Specifically, I will address 3 issues - prophylactic rather than preemptive delivery of CD8+ CMV-specific T cells, the use of CD8+ CMV-specific T cells in the setting of unrelated donor transplantation and a trial of adoptive transfer of CD4+ CMV-specific CTL

This proposal offers the medical opportunity to develop novel approaches to the treatment of immunodeficiency following SCT and will have more general lessons for T cell immunotherapy.</gtr:technicalSummary><gtr:fund><gtr:end>2009-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>538814</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Virginia (UVa)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Tumour Immunology Partnership</gtr:description><gtr:id>B7CB5B14-D5C7-49E8-9302-FC7E04D49329</gtr:id><gtr:impact>18836451 More will follow.</gtr:impact><gtr:outcomeId>D624B567681-1</gtr:outcomeId><gtr:partnerContribution>Providing Reagents, Training and Resources</gtr:partnerContribution><gtr:piContribution>Through my Clinician Scientist Award was able to spend 2 years at the University of Virginia training in Phosphoproteomics and Tumour Immunology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Birmingham Cancer Research UK Centre</gtr:department><gtr:description>Professor Ben Willcox</gtr:description><gtr:id>4253FEB3-8896-4FCE-99EE-490CF7330DBC</gtr:id><gtr:impact>PMID: 19234124, 18836451</gtr:impact><gtr:outcomeId>F3562DE5AEF-1</gtr:outcomeId><gtr:partnerContribution>Joint Studentship</gtr:partnerContribution><gtr:piContribution>Key collaboration for my work. We have started a complimentary collaboration focusing on the recognition of post-transnationally modified antigens.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis Institutes for BioMedical Research (NIBR)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Novartis Vaccines Institute for Global Health (NVGH)</gtr:department><gtr:description>Novartis</gtr:description><gtr:id>DABFB055-1B25-495A-BC5D-141FC30276E6</gtr:id><gtr:impact>Publications, shared expertise</gtr:impact><gtr:outcomeId>kfVCsHQxxZg-1</gtr:outcomeId><gtr:partnerContribution>Providing expertise and resource for immune-based studies</gtr:partnerContribution><gtr:piContribution>Translational links to industry which are critical for future developmental pathways for other areas of activity.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Immune Regulation</gtr:department><gtr:description>MRC Centre for Immune Regulation</gtr:description><gtr:id>762C0C99-C8C0-4C53-8984-60BCA8DE46C4</gtr:id><gtr:impact>All outcomes from this application form.</gtr:impact><gtr:outcomeId>mJVPhTmB3AU-1</gtr:outcomeId><gtr:partnerContribution>Use of facilities and studentships.</gtr:partnerContribution><gtr:piContribution>Member of MRC Centre</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Life and Environmental Sciences</gtr:department><gtr:description>Salmonella</gtr:description><gtr:id>38F03655-CB37-4AA9-8BFF-29D0866A968D</gtr:id><gtr:impact>In this case I have a collaborative paper which is currently at review with Science we have just submitted a revised manuscript which addresses the reviewers comments.&amp;nbsp; This work was carried out whilst I was funded by my MRC fellowship. Manuscript details: Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. One sentence summary: High titers of anti-lipopolysaccharide antibody provide a mechanism to account for the long-standing association between HIV infection and susceptibility to fatal nontyphoidal Salmonella bacteremia. Calman A. MacLennan1-4 James J. Gilchrist1,2,5 Melita A. Gordon2,6,7 Adam F. Cunningham1 Mark Cobbold1 Margaret Goodall1 Robert A. Kingsley8 Joep J. G. van Oosterhout2,7 Chisomo L. Msefula2,4,9 Wilson L. Mandala2,9,10 Denisse L. Leyton11 Jennifer L. Marshall1 Esther N. Gondwe1,2,9 Saeeda Bobat1 Constantino L&amp;oacute;pez-Mac&amp;iacute;as12 Ian R. Henderson11 Eduard E. Zijlstra7 Gordon Dougan8 Mark T. Drayson1 Ian C. M. MacLennan1 Malcolm E. Molyneux2,7,9 1Medical Research Council Centre for Immune Regulation and Clinical Immunology Service, Institute of Biomedical Research, School of Immunity and Infection, University of Birmingham, UK 2Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Malawi 3Division of Medical Microbiology, University of Liverpool, UK 4Department of Microbiology, College of Medicine, University of Malawi, Malawi 5Oxford University Clinical Academic Graduate School Medical Sciences Division, John Radcliffe Hospital, Oxford, UK 6Gastroenterology Unit, University of Liverpool, UK 7Department of Medicine, College of Medicine, University of Malawi, Malawi 8Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK 9Liverpool School of Tropical Medicine, Pembroke Place, University of Liverpool, UK 10Department of Biochemistry, College of Medicine, University of Malawi, Malawi 11Biosciences, School of Immunity and Infection, University of Birmingham, UK 12Medical Research Unit on Immunochemistry, Specialties Hospital, National Medical Centre &amp;quot;Siglo XXI&amp;quot;, Mexican Institute for Social Security, Mexico City, Mexico</gtr:impact><gtr:outcomeId>1AF8507AEC7-1</gtr:outcomeId><gtr:partnerContribution>Reagents</gtr:partnerContribution><gtr:piContribution>This collaboration with CM has led to the isolation of Salmonella-specific antibodies from patients with HIV.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>British Society for Histocompatibility and Immunogenetics</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>681453AC-5F9B-41E8-940A-08738A8AE09C</gtr:id><gtr:impact>Communication of my work to lay people, basic scientists and biomedical scientists.

Potential collaboration with Alex Sette initiated.</gtr:impact><gtr:outcomeId>94677EAD0E3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Birmingham University Clinical Academic Training</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>5E1BC489-05E0-433A-9051-0264292B7199</gtr:id><gtr:impact>Aimed at final year medical students and junior doctors aimed at promoting academic medicine regionally

A number of contacts were made.</gtr:impact><gtr:outcomeId>8CEDE300144</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK NCRI Lymphoma Group Biological Studies Dec 2008</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>23FE7D31-4A0F-411D-AB0E-7711DBE5667B</gtr:id><gtr:impact>Presentation to haematologists/oncologist dissemination information linked to immunotherapy.

Collaborations initiated.</gtr:impact><gtr:outcomeId>C2477855988</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hospital Grand Rounds (Birmingham)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>3D08CC39-C5E0-4413-9A2D-34E0E1B3508D</gtr:id><gtr:impact>Presenting Research at University Hospital Birmingham. Presented to around 50 Hospital physicians. Promoted Immunotherapy as an emerging therapeutic.

Other groups within the UHB are planning to use regulatory T cells as immunotherapy.</gtr:impact><gtr:outcomeId>B334D88D7BB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>624180</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research (A randomised phase II trial of the adoptive transfer of tetramer selected cytomegalovirus-specific cytotoxic T lymphocytes (CMV-CTL) after allogeneic stem cell transplantation (SCT) in patients at risk of CMV disease)</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>C40FF1C1-36D8-4153-9EC4-A61F00B2C3A4</gtr:id><gtr:outcomeId>89005A51B790</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>193959</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research (Characterising and immunologically targeting the phosphoproteome in acute myeloid leukaemia)</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>0A773C76-60EA-41A8-9806-5A95BDEFE76E</gtr:id><gtr:outcomeId>6401BC5DB6A0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UHB Charities</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Queen Elizabeth Hospital Birmingham Charity (QEHB)</gtr:fundingOrg><gtr:id>762FAEA3-572B-41E8-931B-1454AD1D32AB</gtr:id><gtr:outcomeId>5D5584D4F800</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>479249</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant (Direct selection and adoptive transfer of allogeneic adenovirus-specific T lymphocytes to treat adenoviral infection following stem cell transplantation)</gtr:description><gtr:end>2009-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9353BB2C-6915-400F-B09B-C06844014B02</gtr:id><gtr:outcomeId>3B175D1E4470</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>104655</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KKLF funding (Immune Targeting of the Phosphoproteome in Chronic Lymphocytic Leukaemia )</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:id>9511380C-E791-43E2-8BA6-16A1CCC4285F</gtr:id><gtr:outcomeId>0CE559D2BA80</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.</gtr:description><gtr:grantRef>G108/574</gtr:grantRef><gtr:id>0FA6F6E3-0E73-4B7A-8919-BE190021C03E</gtr:id><gtr:impact>PhosImmune Ltd</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>54648a3506e131.37117895</gtr:outcomeId><gtr:patentId>WO 2014036562</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Target peptides for immunotherapy and diagnostics</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A set of target peptides are presented by HLA A*0201, B*0301, B*0702 and B*2705 on the surface of disease cells. They are envisioned to, among other things, stimulate an immune response to the proliferative disease, e.g., colorectal cancer, to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, facilitate antibody recognition of tumor boundaries in surgical pathology samples, act as biomarkers for early detection and/or diagnosis of the disease, and/or act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.</gtr:description><gtr:grantRef>G108/574</gtr:grantRef><gtr:id>F3932900-4209-4272-A086-64E83FAFCF44</gtr:id><gtr:impact>A University of Birmingham Spin-Out: PhosImmune</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>546489fb702a45.54605652</gtr:outcomeId><gtr:patentId>WO 2014039675</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Target peptides for colorectal cancer therapy and diagnostics</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Diagnostic assay to measure serum free ? and ? Immunoglobulin Light Chains in biological fluid.</gtr:description><gtr:grantRef>G108/574</gtr:grantRef><gtr:id>43CD9BF4-D528-47BF-9B58-CAA81BDF21F4</gtr:id><gtr:impact>Possible spin-out in discussion</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>6938C1E21AA</gtr:outcomeId><gtr:patentId>WO2010049672</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>P580141; Use of Monoclonal Antibodies to Assay Serum Free ? and ? Immunoglobulin Light Chains</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A set of phosphorylated peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of melanoma cells. They have the potential to (a) stimulate an immune response to the cancer, (b) to function as immunotherapeutics in adoptive T-cell therapy or as a vaccine, (c) to facilitate antibody recognition of the tumor boundaries in surgical pathology samples, and (d) act as biomarkers for early detection of the disease. Phosphorylated peptides are also presented for other cancers.</gtr:description><gtr:grantRef>G108/574</gtr:grantRef><gtr:id>72EBE37E-40C6-410A-B311-9A6EF786CE15</gtr:id><gtr:impact>PhosImmune Ltd</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>54648acadb5535.90990672</gtr:outcomeId><gtr:patentId>US 20130259883</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Class i mhc phosphopeptides for cancer immunotherapy and diagnosis</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The CMV~ACE/ASPECT study is a phase II randomized study to investigate the use of CytovirTM CMV in combination with conventional antiviral drug therapy for the treatment of CMV reactivation episodes in patients following allogeneic hematopoietic stem cell transplant from an unrelated donor.

This work, although not part of the MRC Clinician Scientist Fellowship, followed on directly from the work.</gtr:description><gtr:id>E9267E88-8CF2-4476-936B-5055735B5559</gtr:id><gtr:impact>Commercial development and progression of CellMedica</gtr:impact><gtr:outcomeId>54651d2f9e8fa2.78170746</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CMV~ACE/ASPECT Study</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:url>http://www.cellmedica.co.uk/clinical-research/cytovir-cmv/ace-aspect/</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Ongoing assay development since 2004</gtr:description><gtr:id>CE7E2964-394F-46C4-BDC6-B62C29BAF27F</gtr:id><gtr:impact>Publications will follow in 2010.</gtr:impact><gtr:outcomeId>D63A9A2FD8E</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Serum Free ? and ? Immunoglobulin Light Chains Assay</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>We initiated a Phase II study as part of my Clinician Scientist Fellowship but had to abandon the trial due to EU legislation. CellMedica took the work and have commercilised the technology via a series of clinical trials. These commercial trial were not directly funded by the fellowship but are directly related to and follow on from the work.</gtr:description><gtr:id>CED79677-20F1-4DA2-9150-A3B650E44FBB</gtr:id><gtr:impact>This trial has led to the expansion and commercial development of CellMedica including establishments of a manufacturing centre.</gtr:impact><gtr:outcomeId>5465122fb435a7.04640399</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CMV-IMPACT: Cytomegalovirus Immunoprophylactic Adoptive Cellular Therapy Study</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:url>http://www.cellmedica.co.uk/technology/our-products/cytovir-immune-reconstitution/cytovir-cmv/</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Phosphopeptide-specific T cell lines.</gtr:description><gtr:id>4719B6C6-FB19-4B86-98EA-B60F606CFFEE</gtr:id><gtr:impact>Ongoing studies with Dr Ben Willcox</gtr:impact><gtr:outcomeId>6C85160EDE4</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>T cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>SeraScience</gtr:companyName><gtr:description>SeraScience is an immunodiagnostic company focused on the development of rapid diagnostic and monitoring immunoassays for haematological malignancies, SeraScience was acquired by Abingdon Health Limited in 2014.</gtr:description><gtr:id>998AF5C3-F69F-4E71-A16C-3C47A0DEAE0F</gtr:id><gtr:impact>The lead diagnostic SeraLite is currently being used within the NHS for the diagnosis and management of patients with myeloma.</gtr:impact><gtr:outcomeId>54650b4139e917.58002913</gtr:outcomeId><gtr:url>http://www.serascience.com/</gtr:url><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>64A8AE2B-5C29-41E9-854A-4611B9656931</gtr:id><gtr:title>Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/826cdc2ce0980c0b971111b73991889a"><gtr:id>826cdc2ce0980c0b971111b73991889a</gtr:id><gtr:otherNames>MacLennan CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>A3U5PtVv5x8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1718F039-AD0F-4297-A7F0-D1E9FD0E841C</gtr:id><gtr:title>Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/900f15085684a59c8ecf7e8ff978e3d3"><gtr:id>900f15085684a59c8ecf7e8ff978e3d3</gtr:id><gtr:otherNames>Nicholls S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>B5CFC838975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82EC0A82-04A3-483E-9A79-B5F1A465CF16</gtr:id><gtr:title>Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa05503531d0b0a9bbbfd821b8cd09b8"><gtr:id>fa05503531d0b0a9bbbfd821b8cd09b8</gtr:id><gtr:otherNames>Cobbold M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>546487439b1b51.27229912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E74C8D1C-DD73-47C5-98D4-27B99D3A7DB1</gtr:id><gtr:title>In treatment-na&amp;iuml;ve and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a504a56bb9fa233e44d7ee8566f2030"><gtr:id>4a504a56bb9fa233e44d7ee8566f2030</gtr:id><gtr:otherNames>Das S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>4A697A1D283</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A18703B-6109-4838-B351-15B642317BAF</gtr:id><gtr:title>HLA-peptide multimer selection of adenovirus-specific T cells for adoptive T-cell therapy.</gtr:title><gtr:parentPublicationTitle>Journal of immunotherapy (Hagerstown, Md. : 1997)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0f99e82017e3de95b0a51325b295d1b"><gtr:id>f0f99e82017e3de95b0a51325b295d1b</gtr:id><gtr:otherNames>Chakupurakal G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1524-9557</gtr:issn><gtr:outcomeId>546487457d4aa0.45345405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CC91D97-D588-4085-BB34-17426CC2F81C</gtr:id><gtr:title>Persistent viral infection in humans can drive high frequency low-affinity T-cell expansions.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4565dafaf87d213d5e13e790513349db"><gtr:id>4565dafaf87d213d5e13e790513349db</gtr:id><gtr:otherNames>Khan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>SAqFNEFwWJ4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C81405DB-B6A1-4854-B3C3-67BC156E02D3</gtr:id><gtr:title>Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1bae0991572df57539f5b539d5e8835"><gtr:id>c1bae0991572df57539f5b539d5e8835</gtr:id><gtr:otherNames>Amrolia PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>1CA67F42090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0BA8196-B984-4C5D-9DB9-F3649C9DEDAB</gtr:id><gtr:title>MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa05503531d0b0a9bbbfd821b8cd09b8"><gtr:id>fa05503531d0b0a9bbbfd821b8cd09b8</gtr:id><gtr:otherNames>Cobbold M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>546486ddf25e70.41518236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CA44B53-6B59-4181-9CAA-8BA4ACD71C12</gtr:id><gtr:title>Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69281c0645e346b9b9c7ad57a9ceff48"><gtr:id>69281c0645e346b9b9c7ad57a9ceff48</gtr:id><gtr:otherNames>Wiesner M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>546487436e3370.68522765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C33208D1-28ED-4162-8EA3-EF89D3845D28</gtr:id><gtr:title>Adenovirus vector-specific T cells demonstrate a unique memory phenotype with high proliferative potential and coexpression of CCR5 and integrin alpha4beta7.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0f99e82017e3de95b0a51325b295d1b"><gtr:id>f0f99e82017e3de95b0a51325b295d1b</gtr:id><gtr:otherNames>Chakupurakal G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>D5DCF03D1D4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DCBAF09-5639-45C6-84D6-0573F6E25519</gtr:id><gtr:title>Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f6d490d60a2b0a44e3b93aa401c8e37"><gtr:id>0f6d490d60a2b0a44e3b93aa401c8e37</gtr:id><gtr:otherNames>Mohammed F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>335C643A0B6</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G108/574</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>78E3B265-B307-4D06-9AB7-1F69471E721F</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>5.4  Surgery</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>